Cyclerion Therapeutics (CYCN) Financials

$3.36

$-26.39 (-88.71%)

As on 08-Sep-2026 16:00EDT

Market cap

$16 Mln

Revenue (TTM)

$2 Mln

P/E Ratio

--

P/B Ratio

3.1

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	1.90	2.07	2.00	--	0.30	3.32
Cost of Revenue	0.73	--	--	1.32	5.58	0.47
Gross Profit	1.17	2.07	2.00	-1.32	-5.28	3.32
Operating Expenses	7.99	7.05	5.63	11.64	13.26	58.52
Operating Profit (EBIT)	-6.82	-4.97	-3.63	-12.95	-18.54	-55.20
Other Income	--	--	--	--	--	--
Profit before Tax	-6.71	-3.53	-3.06	-12.59	-18.25	-51.65
Provision for Tax	--	--	--	8.42	-0.29	0.02
Profit after Tax (Net Income)	-6.71	-3.53	-3.06	-5.26	-44.08	-51.65
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-44.08	-51.65

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	5.09	9.09	8.85	11.29	10.45	48.25
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	--	--	--	--	2.97	1.83
Current Liabilities	1.84	0.90	0.73	2.09	7.63	11.09
Total Liabilities	8.77	9.99	9.58	13.37	18.08	59.33

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	5.42	5.35	5.35	5.35	3.26	3.87
Current Assets	1.51	4.64	4.23	8.02	14.82	55.46
Total Assets	8.77	9.99	9.58	13.37	18.08	59.33
Total Debt*	--	--	--	--	--	--
Net Current Assets	-0.33	3.74	3.50	5.94	7.19	44.37

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-3.31	-4.33	-21.25	-40.61	-36.52
Cash Flow from Investing Activities	--	--	--	10.40	--	1.46
Cash from Financing Activities	--	3.32	--	5.02	0.03	30.79
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-12.03	-7.66	-1.20	-2.13	-20.26	-25.06
Cash EPS ($)	--	-7.66	-1.20	-2.13	-20.23	-24.83
Adjusted Book Value ($)	--	19.72	3.48	4.56	4.80	23.41
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-7.19	-1.70	-8.59	-18.66	-17.72
Free Cash Flow per Share ($)	--	-7.19	-1.70	-8.59	-18.66	-17.72

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-39.34	-30.36	-48.42	-150.19	-67.30
ROE (%)	-94.65	-39.34	-30.36	-48.42	-150.19	-95.87
ROA (%)	-70.81	-36.07	-26.64	-33.47	-113.88	-59.12
EBIT Margin (%)	--	--	-181.40	--	-6,143.43	-1,635.96
Net Margin (%)	-353.00	-170.11	-152.85	--	-14,841.08	-1,555.63
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	-12.60	0.04	--	-1.00	-0.91	0.45
EBIT Growth (%)	--	--	62.39	47.13	66.41	34.51
Net Profit Growth (%)	-244.66	-15.41	41.92	88.06	14.66	33.62
EPS Growth (%)	-1,520.13	-5.38	0.44	0.89	0.19	0.50
Book Value Growth (%)	200.16	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-0.17	-2.68	-1.57	-0.03	-0.07
Price / Book Value	3.15	0.06	0.93	0.73	0.14	0.07
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	0.56	0.75	-1.62	-0.07	0.66	0.94
Close Price ($)	23.73	8.89	22.54	23.45	91.87	240.80
High Price ($)	59.36	43.75	39.90	133.97	264.60	966.00
Low Price ($)	7.19	8.12	8.89	12.25	49.00	208.60
Market Cap ($ Cr)	15.73	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	--	--	--	--	--
Short term debt to equity ratio	--	--	--	--	--	--
Current Ratio	0.82	5.15	5.83	3.85	1.94	5.00
Quick Ratio	0.82	--	--	--	1.84	4.92
Interest Coverage	--	--	--	--	-62.06	-3,394.63

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	48.22	27.80	--	32.32	3.01
Asset Turnover	0.20	0.21	0.17	--	0.01	0.04
Receivable days	--	137.01	50.77	--	120.52	12.49
Inventory Days	--	--	--	223.59	56.73	674.78
Payable days	--	--	--	578.84	157.06	1,151.85
Cash Conversion Cycle	--	--	--	--	20.19	-464.58

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.